Clinical trial
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in…
NCT00393445 · Ludwig-Maximilians - University of Munich, Other · Completed
Key facts
| NCT number | NCT00393445 |
|---|---|
| Title | Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans |
| Official title | Effect of GLP-1 on Glucose Metabolism in Healthy Subjects and Patients With T2DM. Part 1: A Pilot Study to Assess the Efficacy of Exendin(9-39)Amide as a GLP-1 Receptor Antagonist in Healthy Subjects |
| Lead sponsor | Ludwig-Maximilians - University of Munich, Other |
| Collaborators | German Research Foundation Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hyperglycemia |
| Intervention type | Drug |
| Interventions | GLP-1 control, GLP-1 and Exendin(9-39) 300, saline control, GLP-1 and Exendin(9-39) 600, GLP-1 and Exendin(9-39) 900, GLP-1 and Exendin(9-39) 1200 |
| Enrollment | 6 |
| Start date | Nov 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Oct 27, 2006 |
| Last update posted | Oct 4, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: